Unibest

Pharmaceutical intermediates

Capmatinib Hydrochloride Intermediates

1 pharmaceutical intermediate for Capmatinib Hydrochloride. Indication: Non-small cell lung cancer.

Submit a ProjectAll intermediates

About Capmatinib Hydrochloride

Originator
Incyte Corp; Novartis Pharmaceutical Corp
Indication
Non-small cell lung cancer
Approved Date
05/06/2020
DS/DP
11/19/2027

Available intermediates

1 intermediate currently listed for Capmatinib Hydrochloride. Request specifications, documentation or a quotation for any item below.

Capmatinib Hydrochloride intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
1-[2-Chloro-1-hydroxy-3-(6-quinolinyl)propyl]-2,5-pyrrolidinedione1197377-31-3//

Other programs under C

Cabozantinib S-malateCalcipotriolCalcitriolCamlipixantCanagliflozinCangrelor TetrasodiumCapivasertib Carfilzomib

Building toward Capmatinib Hydrochloride?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →